1. Canada Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Manzo Pharmaceuticals, Inc.

Manzo Pharmaceuticals, Inc.

OOTC:MNZO
0.00
USD
0.00
(0.00%)
-0.59EPS
Manzo Pharmaceuticals, Inc.
OTC:MNZO
(OTC Markets)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2003
2004
TTM
USD
0.93
0.89
- -
Revenue per Share
-1.23
-1.2
-0.59
Basic EPS, GAAP
-0.49
-0.32
- -
Free Cash Flow per Basic Share
- -
- -
- -
Dividend per Share
-5.29
-6.45
-6.45
Book Value per Share
-5.29
-6.45
-6.45
Tangible Book Value per Share
3
3
3
Basic Weighted Avg Shares
3
3
- -
Sales/Revenue/Turnover
-108.14
-104.16
- -
Operating Margin (%)
- -
- -
- -
Depreciation Expense
-4
-4
-2
Net Income, GAAP
- -
- -
- -
Effective Tax Rate (%)
-131.63
-135.2
- -
Profit Margin (%)
-22
-24
-24
Working Capital
- -
- -
- -
LT Debt
-18
-23
-23
Total Equity
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
Return on Capital (%)
- -
- -
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'04
ST Debt
7
LT Borrowings
- -
LT Finance Leases
- -
Preferred Equity and Hybrid Capital
- -
Shares Outstanding
3
Market Capitalization
- -

Working Capital

USD

•

in mil. unless spec.
Dec'04
Total Current Assets
- -
Cash, Cash Equivalents & STI
- -
Accounts Receivable, Net
- -
Inventories
- -
Total Current Liabilities
24
Payables & Accruals
15
ST Debt
7
Deferred Revenue
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
21.88%
Free Cash Flow
- -
- -
-29.96%
Net Income, GAAP
- -
- -
4.99%
Sales/Revenue/Turnover
- -
- -
2.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2003
- -
- -
- -
- -
3
2004
- -
- -
- -
- -
3
2005
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2003
- -
- -
- -
- -
-1.23
2004
- -
- -
-0.29
-0.3
-1.2
2005
- -
- -
-0.23
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2003
- -
- -
- -
- -
- -
2004
- -
- -
- -
- -
- -
2005
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Manzo Pharmaceuticals, Inc. Manzo Pharmaceuticals, Inc. (MNZO), a specialty pharmaceutical company incorporated in 1980 and headquartered in Milford, Pennsylvania, engages in the research, development, testing, and commercialization of patented and non-patented probiotic and natural remedy solutions targeting digestive health issues; its primary product is Lacto-Freedom, a patented probiotic formulation featuring L. acidophilus MPH734 that aids in the digestion of lactose-containing dairy foods for individuals with lactose intolerance by preventing gas, bloating, diarrhea, and cramps following a seven-day regimen with effects reported to last up to six months; the company also develops a natural remedy for colic in babies. All products are manufactured in the USA, with Lacto-Freedom co-developed by founder and CEO Kenneth Manzo, a licensed pharmacist in New York, New Jersey, and Pennsylvania, in collaboration with Celprogen, Inc., a California-based biotech firm. The company, formerly known as Fortune Oil & Gas, Inc., changed its name to Manzo Pharmaceuticals, Inc. in September 2014 to reflect its strategic shift from oil and gas to pharmaceuticals, and it operates primarily in the United States with a small team of 12 employees focused on the healthcare sector's probiotics and infant care segments.